ABSTRACT
The development of new radiopharmaceuticals for the detection of hidden infection foci has great relevance for early detection and the selection of the correct treatment, particularly in immunosuppressed patients. In that sense, the labelling of antimicrobial peptides (AMPs) that are capable of binding specifically to the pathogenic microorganism which causes the infection, should provide a sufficiently specific agent, able to distinguish an infection from a sterile inflammation. Defensins are particularly interesting molecules with antimicrobial activity, the EcgDf1 defensin was identified from the genome of a Uruguayan native plant, Erythrina crista-galli, the 'Ceibo' tree. Our group has previously reported a synthetic biologically active short analogue EcgDf21 (ERFTGGHCRGFRRRCFCTKHC) successfully labelled with 99mTc. Herein we present a shorter analogue which also preserves the γ-core domain, as a pharmacophore for a potential infection detection agent. This peptide was derivatized with the bifunctional chelating agent 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) through a lysine linker in the amino-terminal group (NOTA-KGHCRGFRRRC) and radiolabelled with 68Ga ([68Ga]Ga-NOTA-K-EcgDf1(10)). The [68Ga]Ga-NOTA-K-EcgDf1(10) labelling procedure rendered a product with high radiochemical purity and stability in the labelling milieu. The Log P value indicated that the complex has a hydrophilic behaviour, confirmed by the biodistribution profile. The [68Ga]Ga-NOTA-K-EcgDf1(10) complex demonstrated specific binding to cultures of Candida albicans and Aspergillus niger. Its biodistribution showed renal elimination and low accumulation in the rest of the body. It was possible to successfully differentiate sterile inflammation from infection by PET images in nude mice with a target/non-target ratio of 3.3 for C. albicans and 3.7 for A. niger, respectively.
Subject(s)
Defensins , Gallium Radioisotopes , Positron-Emission Tomography , Radiopharmaceuticals , Animals , Humans , Mice , Amino Acid Sequence , Defensins/chemistry , Gallium Radioisotopes/chemistry , Peptides/chemistry , Positron-Emission Tomography/methods , Radiopharmaceuticals/chemistry , Tissue Distribution , Organotechnetium Compounds/chemistryABSTRACT
Opportunistic infections are a problem of great relevance in public health and the precise detection and localization of infection in the early stages of the disease is of great importance for patient management as well as cost containment. Our proposal seeks to contribute to developing a new agent that meets the needs of diagnosis and follow-up of fungal and bacterial infections, focused on the design of a radiotracer with the potential for recognition of hidden infection foci. Defensins are plant antimicrobial peptides that not only show activity against plant pathogens but also against human ones. A short analogue of EcgDf1 defensin, EcgDf21d (NH2 -ERFTGGHCRGFRRRCFCTKHC-COOH), was labelled through the formation of a 99m Tc-HYNIC complex which was assessed for physicochemical and biological behaviour both in vitro and in vivo. The [99m Tc]Tc-HYNIC-EcgDf21 labelling procedure rendered a single product with remarkably high RCP and stability in the labelling milieu. The Log p value indicated that [99m Tc]Tc-HYNIC-EcgDf21 has a hydrophilic behaviour, confirmed by the biodistribution profiles. The optimal uptake value was obtained for Candida albicans infection model reaching a lesion/muscle ratio of 3, this correlates with in vitro binding studies, and the lesion can be definitely observed in the scintigraphic images.
Subject(s)
Bacterial Infections , Candidiasis , Humans , Bacterial Infections/diagnostic imaging , Defensins , Radionuclide Imaging , Technetium , Tissue DistributionABSTRACT
In vivo receptor targeting with radiolabelled peptide-based probes is an attractive approach for the development of novel radiotracers for molecular imaging. This work presents the development and characterization of two novel neuropeptide Y analogues labelled with a positron emitter 68 Ga, for potential use in breast cancer imaging. Both analogues share the same amino acid sequence and were derivatized with NOTA through either a lysine linker (L1) or an acetylated lysine (L2). In both cases, a single product with radiochemical purity higher than 95% was obtained. The two complexes were hydrophilic, showed remarkable in vitro stability, good cellular uptake, binding affinity in the nanomolar range and high cellular internalization rate. Biodistribution studies revealed low blood uptake and elimination through the urinary tract. The addition of an acetyl group in the spacer increased the lipophilicity of C2 and modified the reactivity of the ε-amino group of the lysine which resulted in lower protein binding and lower percentage of injected dose in bladder and urine. The tumour versus muscle ratio was (3.8 ± 0.4) for 68 Ga-L1 and (4.7 ± 0.4) for 68 Ga-L2. These results encourage performing further studies in order to complete the evaluation of both tracers as potential radiopharmaceutical for breast cancer imaging.
Subject(s)
Breast Neoplasms/diagnostic imaging , Gallium Radioisotopes/chemistry , Neuropeptide Y/chemistry , Radiopharmaceuticals/chemistry , Amines/chemistry , Amino Acid Sequence , Animals , Biological Transport , Cineradiography , Female , Humans , Lysine/chemistry , Mice, Nude , Neoplasms, Experimental , Neuropeptide Y/blood , Neuropeptide Y/pharmacokinetics , Neuropeptide Y/urine , Protein Binding , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/urine , Staining and Labeling , Structure-Activity Relationship , Tissue DistributionABSTRACT
OBJECTIVES: Treatment of leishmaniasis remains a challenge, especially due to the need for multiple painful injections, the toxicity of current drugs against the disease, their lack of efficacy and, lately, drug resistance. The aim of this study was to demonstrate the biological behaviour of 3-nitro-2'-hydroxy-4',6'-dimethoxychalcone (CH8) in a murine model of cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). METHODS: To evaluate its biological behaviour, compound CH8 was radiolabelled with technetium-99m (99mTc) using the direct reaction. Groups of animals infected with ether Leishmania infantum (as a model for VL) or Leishmania amazonensis (as a model for CL) were administered CH8-99mTc orally or subcutaneously, respectively, and its biodistribution was evaluated. RESULTS: Oral administration of CH8-99mTc resulted in poor absorption. However, the absorbed drug was expressively taken up in the blood and liver, the main organ infected in VL. CH8-99mTc administered by the subcutaneous route showed a poor distribution and significant uptake in the left ear, suggesting a local effect in the skin. In addition, the VL and CL infection models did not considerably alter the biodistribution profile by the oral and subcutaneous routes, respectively. CONCLUSION: These results suggest that CH8 is a promising candidate for oral treatment of VL and for intralesional treatment of CL, showing a prominent local effect.
Subject(s)
Chalcones/pharmacokinetics , Leishmania infantum/drug effects , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Visceral/drug therapy , Animals , Female , Mice , Mice, Inbred BALB C , Radioisotopes , Technetium Tc 99m Pentetate , Tissue DistributionABSTRACT
Pulse radiolabelling of cells with radioactive amino acids is a common method for studying the biosynthesis of proteins. The labelled proteins can then be immunoprecipitated and analysed by electrophoresis and imaging techniques. This chapter presents a protocol for the biosynthetic labelling and immunoprecipitation of pancreatic islet proteins which are known to be affected in psychiatric disorders such as schizophrenia.